Glomerulonephritis Market By Disease Type (IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, Chronic Glomerulonephritis, Acute Glomerulonephritis, Other Glomerular Disorders); By Treatment Type (Immunosuppressive Therapy, Corticosteroids, Biologic Therapies, ACE Inhibitors and ARBs, Supportive Care, Diuretics); By Route of Administration (Oral Administration, Injectable Administration, Intravenous Administration); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Nephrology Centers, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Big Is the Glomerulonephritis Market—and Which Therapies Are Redefining Its Future?

The Global Glomerulonephritis (GN) Market was valued at USD 4.15 billion in 2025 and is projected to reach USD 7.43 billion by 2032, expanding at a CAGR of 8.65% during 2026–2032, according to Strategic Market Research.

 

Glomerulonephritis refers a broad spectrum of inflammatory and immune-mediated kidney disorders that affect the glomeruli, the filtration units of the kidneys. Progressive damage to these structures can impair renal function and eventually lead to kidney failure.

 

In 2021 people were estimated to be living with CKD attributable to glomerulonephritis, while broader GBD-based estimates place global prevalent GN-CKD cases at approximately 6.9–17.3 million. Population growth and aging have contributed to an estimated 77% increase in incidence and 81% increase in prevalence over recent decades. Acute glomerulonephritis accounts for approximately 528,368 new cases annually, with around 35,452 active prevalent cases worldwide at a given time.

 

In the United States, reported estimates place GN at 10–15% of glomerular-disease diagnoses and 25–30% of end-stage renal disease cases requiring dialysis or transplantation. Approximately 160,000 Americans have diagnosed IgAN, with pooled prevalence estimates of 542–627 cases per million people. GN incidence is around 10 cases per 100,000 patient-years in general health-plan populations but rises to approximately 134 per 100,000 patient-years among older Medicare-eligible patients.

 

IgA nephropathy has emerged as a key area of innovation, with new therapies targeting pathways such as endothelin signaling, complement activation, and APRIL-mediated immune responses. Recent approvals, including Vanrafia (atrasentan) for reducing proteinuria in adults with primary IgAN at risk of progression and Voyxact (sibeprenlimab-szsi), an APRIL-targeting therapy, demonstrate the growing importance of targeted treatment strategies. Additionally, Fabhalta (iptacopan) has expanded complement-focused treatment options across IgAN and C3 glomerulopathy.

 

Filspari (sparsentan) became the first FDA-approved treatment for FSGS, addressing a historically underserved patient population. Complement-mediated disorders have also gained dedicated treatment options, with Empaveli (pegcetacoplan) approved for C3G and primary IC-MPGN, further strengthening the role of complement inhibition in GN management. These innovations are increasing treatment availability for patients with limited disease-specific options and intensifying competition among pharmaceutical companies developing immune-targeted and renal-protective therapies.

 

Overall, the Glomerulonephritis Market is entering a new phase of growth driven by the transition toward precision nephrology and personalized kidney care. Increasing disease awareness, improved diagnosis, rising demand for kidney-preserving therapies, and a growing pipeline of targeted treatments across IgAN, FSGS, lupus nephritis, C3G, and other immune-mediated disorders are expected to expand the addressable market. Continued innovation in complement inhibitors, APRIL blockers, endothelin pathway therapies, and biologics will further shape competition and support sustained market growth through 2032.

 

Leading and Fastest-Growing Subsegments Of Glomerulonephritis Market

By Disease Type

IgA Nephropathy — Leading and Fastest-Growing Disease Type: IgA nephropathy led the disease-type segment with a 31.5% share, representing USD 1.31 billion in 2025, and is projected to record the fastest CAGR of 9.4% during 2026–2032. Its strong market position reflects its prominence among primary glomerular diseases, biopsy-based diagnosis and rapid expansion of disease-specific treatment options. The availability of targeted therapies addressing endothelin signaling, complement activation, APRIL and BAFF/APRIL pathways is transforming IgAN from a largely supportive-care market into a competitive specialty-nephrology segment.

 

By Treatment Type

Immunosuppressive Therapy — Leading Treatment Type: Immunosuppressive therapy held the largest treatment share at 28.0%, representing USD 1.16 billion in 2025, and is projected to expand at an 8.9% CAGR during 2026–2032. Its leadership reflects continued clinical use across lupus nephritis, severe immune-mediated glomerular disease, membranous nephropathy and selected vasculitic conditions. Mycophenolate, calcineurin inhibitors and other immunomodulators also remain important treatment backbones as newer targeted biologics are increasingly added to combination regimens.

Biologic Therapies — Fastest-Growing Treatment Type: Biologic therapies represented 18.0% of the market, equivalent to USD 0.75 billion in 2025, and are projected to record the fastest treatment CAGR of 11.2%. Expansion is being supported by movement toward pathway-specific therapy, including APRIL inhibition, dual BAFF/APRIL targeting, complement inhibition and B-cell depletion. These therapies provide greater disease-specific differentiation than conventional broad immunosuppression and are expanding the value of specialty renal treatment.

 

By Route of Administration

Oral Administration — Leading Route: Oral administration dominated with a 58.0% share, representing USD 2.41 billion in 2025, and is projected to grow at an 8.1% CAGR during 2026–2032. Its leadership reflects the chronic outpatient nature of many glomerular diseases and the availability of oral targeted therapies, corticosteroids, immunosuppressants and kidney-protective medicines. Oral dosing also supports prolonged treatment without requiring repeated infusion-center visits.

Injectable Administration — Fastest-Growing Route: Injectable administration accounted for 27.0% and USD 1.12 billion in 2025 and is projected to record the fastest route CAGR of 9.5%. Growth is being supported by subcutaneous biologics with weekly or monthly administration, allowing targeted immune therapy to move closer to home-based management while retaining specialist oversight.

 

By Distribution Channel

Hospital Pharmacies — Leading Distribution Channel: Hospital pharmacies held the largest share at 52.0%, representing USD 2.16 billion in 2025, and are projected to grow at an 8.4% CAGR. Their leadership reflects the role of hospitals in treating severe glomerular inflammation, administering intravenous biologics, initiating complex immunosuppressive regimens and managing patients with acute kidney deterioration or other complications.

Online Pharmacies — Fastest-Growing Distribution Channel: Online pharmacies represented 14.0% and USD 0.58 billion in 2025 and are projected to record the fastest distribution-channel CAGR of 11.0%. Specialty-pharmacy networks, home delivery and increasing use of long-term oral and self-administered therapies are expanding this channel, particularly for high-value renal medicines requiring structured refill and patient-support services.

 

By End User

Hospitals & Clinics — Leading End User: Hospitals & clinics dominated with a 55.0% share, representing USD 2.28 billion in 2025, and are projected to expand at an 8.2% CAGR. Their leadership reflects their involvement throughout the GN care pathway, including renal biopsy, acute disease management, management of severe immune-mediated kidney injury, intravenous therapy and multidisciplinary treatment involving nephrologists, rheumatologists and other specialists.

Specialty Nephrology Centers — Fastest-Growing End User: Specialty nephrology centers accounted for 30.0% and USD 1.25 billion in 2025 and are projected to record the fastest end-user CAGR of 10.1%. Their role is becoming more important as targeted therapies require accurate disease classification, proteinuria measurement, eGFR monitoring, treatment-eligibility assessment and longer-term specialist follow-up.

 

By Geography

North America — Leading Regional Market: North America held the largest regional share at 38.0%, representing USD 1.58 billion in 2025, and is projected to expand at an 8.3% CAGR during 2026–2032. The region leads because of strong nephrology infrastructure, high diagnosis and specialist-treatment activity, rapid introduction of newly approved IgAN, FSGS, C3G and lupus nephritis therapies, established specialty-pharmacy systems and substantial pharmaceutical development activity in immune-mediated kidney disease.

Asia Pacific — Fastest-Growing Regional Market: Asia Pacific represented 22.0% of the market, equivalent to USD 0.91 billion in 2025, and is projected to record the fastest regional CAGR of 10.2%. The region's expansion is supported by the strong clinical presence of IgAN, increasing specialist renal care, broader access to kidney biopsy and advanced treatment, and continuing geographic expansion of targeted IgAN therapies into markets such as Japan.

 

Disease Types Defining the Next Wave of Glomerulonephritis Market Opportunity

IgA nephropathy accounted for 31.5% of the Glomerulonephritis Market, representing USD 1.31 billion in 2025, and is projected to expand at a 9.4% CAGR during 2026–2032. Its leadership reflects a comparatively large diagnosed population, biopsy-based identification and the rapid conversion of IgAN from a primarily supportive-care disease into a multi-product specialty market. U.S. epidemiology estimated approximately 198,887–208,184 prevalent IgAN patients in 2021. Companies such as Travere Therapeutics, Novartis and Otsuka now compete through endothelin/angiotensin blockade, complement inhibition and APRIL inhibition, respectively, creating a differentiated treatment sequence rather than a single dominant drug class.

Lupus nephritis represented the largest segment at 23.0% share (USD 0.95 billion), supported by expanding biologic and combination immunosuppressive therapies. Membranous nephropathy accounted for 16.5% (USD 0.68 billion), benefiting from B-cell-targeted treatments, while Chronic glomerulonephritis held 14.0% (USD 0.58 billion) through continued demand for kidney-protective therapies. Acute glomerulonephritis and other disorders, including FSGS and complement-mediated diseases, represent emerging opportunities as targeted therapies advance.

 

The Glomerulonephritis Market’s Shift Toward Targeted Therapies

Immunosuppressive therapy held the largest treatment share at 28.0%, representing USD 1.16 billion in 2025, and is projected to grow at an 8.9% CAGR through 2032. Mycophenolate, calcineurin inhibitors, cyclophosphamide and other immune-modifying medicines remain important in lupus nephritis, severe inflammatory GN and selected membranous nephropathy or vasculitic disease. Their position is increasingly changing from standalone broad immune suppression toward combination backbones used with disease-specific biologics; NICE, for example, recommends obinutuzumab with mycophenolate for defined active lupus nephritis.

Biologic therapies represented 18.0% of the market, or USD 0.75 billion in 2025, and are projected to record the fastest treatment CAGR at 11.2%. Their expansion reflects movement toward pathway-specific intervention rather than nonspecific immune suppression. Otsuka's VOYXACT selectively blocks APRIL, Vera's TRUTAKNA inhibits BAFF and APRIL, and Roche's GAZYVA depletes CD20-positive B cells. Vertex's povetacicept, a dual BAFF/APRIL inhibitor under FDA review for IgAN, could further intensify this category if approved.

 

The Administration Routes Reshaping the Glomerulonephritis Market

Oral administration dominated with a 58.0% share, representing USD 2.41 billion in 2025, and is projected to expand at an 8.1% CAGR during 2026–2032. Long-duration renal treatment favors oral medicines that can be incorporated into outpatient care. FILSPARI, VANRAFIA, FABHALTA, LUPKYNIS and targeted-release budesonide illustrate the breadth of oral therapy now available across IgAN, lupus nephritis and complement-mediated renal disease. The competitive advantage of oral dosing is increasingly linked to long-term adherence and reduced treatment-center visits rather than convenience alone.

Injectable administration accounted for 27.0% of the market, equivalent to USD 1.12 billion in 2025, and is projected to grow at a 9.5% CAGR. Self-administered biologics are strengthening this category: VOYXACT is administered subcutaneously every four weeks, while TRUTAKNA uses weekly subcutaneous dosing. Vertex is also developing povetacicept with every-four-week administration, giving the injectable segment a growing role in long-term specialist-managed therapy without requiring routine infusion-center attendance.

 

The New Routes Reshaping Glomerulonephritis Market Access

Hospital pharmacies held 52.0% of the market, representing USD 2.16 billion in 2025, and are projected to grow at an 8.4% CAGR. Their leading position reflects the management of severe renal inflammation, intravenous biologics, acute complications and treatment initiation within specialist hospital systems. Products requiring infusion or close clinical monitoring maintain the importance of hospital pharmacy infrastructure even as outpatient therapy expands.

Online pharmacies represented 14.0% of the market, or USD 0.58 billion in 2025, and are projected to record the fastest distribution-channel CAGR of 11.0%. The segment benefits from home delivery and specialty-pharmacy models for chronic oral and self-administered therapy. Aurinia, for example, distributes LUPKYNIS in the United States through specialty pharmacies and a specialty distributor, illustrating how high-value renal medicines increasingly use controlled outpatient distribution networks.

 

The End Users Reshaping the Glomerulonephritis Market

Hospitals & clinics dominated the end-user segment with a 55.0% share, representing USD 2.28 billion in 2025, and are projected to expand at an 8.2% CAGR. Hospitals manage renal biopsy, acute kidney deterioration, severe immune-mediated disease, infusion therapy and complications requiring multidisciplinary nephrology, rheumatology or pathology input. Their market position is therefore broader than pharmaceutical dispensing alone.

Specialty nephrology centers accounted for 30.0% of the market, equivalent to USD 1.25 billion in 2025, and are projected to record the fastest end-user CAGR of 10.1%. Their importance is increasing because newer GN medicines require precise diagnosis, proteinuria assessment, eGFR monitoring, treatment-eligibility decisions and management of specialist safety requirements. The expansion of indication-specific IgAN, FSGS, C3G and lupus nephritis therapy places nephrologists at the center of commercial adoption.

 

Regional Dynamics Shaping the Glomerulonephritis Market

North America accounted for 38.0% of the Glomerulonephritis Market, representing USD 1.58 billion in 2025, and is projected to expand at an 8.3% CAGR during 2026–2032. The region leads because the United States has a large specialist-treated renal population and has become the first major launch market for several recent IgAN, FSGS, C3G and lupus nephritis medicines. U.S. IgAN prevalence was estimated at approximately 198,887–208,184 patients in 2021. Commercialization efforts from Travere, Novartis, Otsuka, Vera and Roche are establishing multiple specialty-drug pathways, while Vertex's accepted povetacicept BLA could add another IgAN entrant before the end of 2026.

Asia Pacific represented 22.0% of the market, or USD 0.91 billion in 2025, and is projected to record the fastest regional CAGR of 10.2%. IgAN has strong clinical visibility across several Asian nephrology systems, making the region strategically important for new product launches and trials. Chugai filed a Japanese New Drug Application for sparsentan in June 2026, using international and Japanese clinical evidence, while multinational IgAN programs from Novartis and Otsuka include substantial Asian trial participation.

 

Leading Innovators Shaping the Glomerulonephritis Market

Competition increasingly centers on disease-specific efficacy, kidney-function preservation, safety, route of administration, dosing frequency, specialist access, indication expansion and pipeline breadth. IgAN has become the most crowded competitive field, while FSGS, C3G/IC-MPGN, lupus nephritis and primary membranous nephropathy offer more concentrated opportunities. Companies capable of using a nephrology commercial platform across several immune-mediated kidney diseases have an advantage over single-indication entrants.

Travere Therapeutics — Leading Rare-Kidney Disease Specialist

Travere Therapeutics is a specialized biopharmaceutical company focused on developing therapies for rare kidney and metabolic diseases, with its glomerulonephritis portfolio centered on IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and other immune-mediated kidney disorders. The company’s key growth driver is FILSPARI (sparsentan), an oral dual endothelin type A receptor and angiotensin II type 1 receptor antagonist designed to reduce proteinuria and slow progressive kidney damage by targeting two important disease pathways. In 2026, FILSPARI strengthened Travere’s position in the GN market after receiving FDA approval for reducing proteinuria in adults and children aged eight years and older with FSGS without nephrotic syndrome, becoming the first approved therapy for this rare kidney condition and providing a significant first-mover advantage. By addressing both IgAN and FSGS, Travere is expanding beyond a single indication and leveraging its expertise in rare nephrology. The company has also demonstrated strong commercial momentum, with U.S. FILSPARI net product sales reaching USD 141.1 million in Q2 2026, compared with USD 71.9 million in Q2 2025. Through continued expansion of FILSPARI and its focus on targeted therapies for rare glomerular diseases, Travere Therapeutics is positioned as a leading specialized competitor in the evolving glomerulonephritis treatment landscape.

Novartis — Leading Multi-Asset Targeted Kidney-Therapy Competitor

Novartis has one of the broadest targeted kidney-disease portfolios in the Glomerulonephritis Market, with commercial and clinical programs focused on IgA nephropathy (IgAN), C3 glomerulopathy (C3G), and other progressive immune-mediated kidney diseases. The company differentiates itself through a multi-mechanism approach, including alternative complement inhibition, endothelin receptor blockade, and immune pathway modulation. Its portfolio includes VANRAFIA (atrasentan), an oral endothelin type A receptor antagonist approved by the FDA in 2025 to reduce proteinuria in adults with primary IgAN at risk of rapid progression, supported by the large-scale ALIGN trial program. Novartis further strengthened its IgAN franchise with FABHALTA (iptacopan), a complement inhibitor approved to slow kidney-function decline in adults with primary IgAN, with Phase III APPLAUSE-IgAN results demonstrating improved renal outcomes compared with placebo. The company is also advancing zigakibart, an investigational anti-APRIL biologic, expanding its immune-targeted pipeline. With complementary therapies targeting different disease pathways, Novartis is positioned as a key player in precision nephrology, particularly across IgAN, C3G, and other immune-mediated renal disorders.

Other Competitive Companies

• Otsuka Pharmaceutical: Competes primarily through VOYXACT (sibeprenlimab), an APRIL-targeting biologic for IgAN, while also participating in lupus nephritis through its voclosporin partnership with Aurinia.

• Vera Therapeutics: Entered the IgAN market with FDA-approved TRUTAKNA (atacicept), differentiating through dual BAFF and APRIL inhibition.

• Vertex Pharmaceuticals: Is an emerging competitor through investigational povetacicept, a dual BAFF/APRIL inhibitor under FDA review for IgAN and also being developed in primary membranous nephropathy.

• Roche: Competes through GAZYVA/GAZYVARO (obinutuzumab) in lupus nephritis and is pursuing expansion into primary membranous nephropathy through B-cell depletion.

 

Glomerulonephritis Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.15 Billion
Revenue Forecast in 2032	USD 7.43 Billion
Overall Growth Rate	CAGR of 8.65% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, By End User, By Geography
By Disease Type	IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, Chronic Glomerulonephritis, Acute Glomerulonephritis, Other Glomerular Disorders
By Treatment Type	Immunosuppressive Therapy, Corticosteroids, Biologic Therapies, ACE Inhibitors & ARBs, Supportive Care, Diuretics
By Route of Administration	Oral Administration, Injectable Administration, Intravenous Administration
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By End User	Hospitals & Clinics, Specialty Nephrology Centers, Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing prevalence of immune-mediated kidney disorders; growing diagnosis of IgA nephropathy and other glomerular diseases; expanding use of targeted biologics and complement inhibitors; rising demand for kidney-preserving therapies and precision nephrology
Customization Option	Available upon request